Advanced Filters
noise

Nasopharyngeal Cancer Clinical Trials

A listing of Nasopharyngeal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 186 clinical trials
Y Yu-xian Yang

Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma

In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy. The participants will be randomly assigned to two groups. The experimental group will receive online adaptive radiotherapy (ART) during the radiotherapy process, with a smaller …

18 - 70 years of age All Phase 3

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.

18 years of age All Phase 2
H Hai-Qiang Mai, MD,PhD

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy. Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST1.1 after two cycles induction chemotherapy will have concurrent chemoradiotherapy. MRI, CT …

18 - 70 years of age All Phase 2
S Shiran Sun, Dr.

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy

18 - 70 years of age All Phase 2
L Liantao Li, M.D., Ph.D.

EBV CAR-T Cells for Nasopharyngeal Carcinoma

The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC

18 - 75 years of age All Phase N/A
Z Zhong-Guo liang, PhD

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

18 - 65 years of age All Phase 3
X Xiaozhong Chen, MD

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

- 70 years of age All Phase N/A
H HanYu wang, PHD

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT alone.

18 - 70 years of age All Phase 3
S Shereen Issa, MD

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of life.However distant failure is still the main challenging reason of poor survival Addition of systemic therapy to concurrent CRT is widely used …

18 - 70 years of age All Phase 3
S Shaojun Lin

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy alone in high-risk nasopharyngeal carcinoma

18 - 69 years of age All Phase 3

Simplify language using AI